Track topics on Twitter Track topics that are important to you
GW Pharmaceuticals has raised $31.2m via an IPO on NASDAQ. With pro forma cash of c £42m, GW is well capitalised to execute its commercial and R&D strategy. Our revised DCF valuation of £178m ($275m), or 101p/share, equates to $18.90 per ADS. This could rise to £213m ($331m), equivalent to $22.60 per ADS, if Sativex is approved for cancer pain. The R&D pipeline and US opportunity for Sativex in MS spasticity currently represents pure upside to our model.
Source: Edison InvestmentNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...